BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-43@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Novo Nordisk A/S — Cagrilintide [May 2027]
DESCRIPTION:Phase 3 primary completion: Weight Loss in People Living With O
 verweight or Obesity Following Treatment With Cagrilintide.\nSource: https
 ://clinicaltrials.gov/study/NCT07220642\nhttps://catalystbrief.girapphe.co
 m/e/43?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/43?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
